Physician profile
Eric Hemminger
NPI 1104027085
$2,767.26
in general payments reported to CMS, 2019-2025
23 companies · $442 in 2025
The $442 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $126 · 2020: $198 · 2021: $258 · 2022: $423 · 2023: $699 · 2024: $621 · 2025: $442.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,436 · Travel and Lodging: $325.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,436.22 |
| Travel and Lodging | $325.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Heartflow, INC. | $1,037.06 | 2022-2025 | Ffrct |
| Abbott Laboratories | $526.51 | 2020-2025 | Aveir, Jot Dx |
| Boston Scientific Corporation | $244.48 | 2019-2024 | Watchman Access System |
| Cleerly, INC. | $139.64 | 2024 | Cleerly Ischemia, Cleerly Labs |
| Astrazeneca Pharmaceuticals Lp | $128.91 | 2024-2025 | Wainua |
| Pfizer INC. | $128.88 | 2019-2025 | |
| Amgen INC. | $69.22 | 2022-2025 | Repatha, Repatha |
| Biosense Webster, INC. | $55.36 | 2025 | Carto 3 |
| E.R. Squibb & Sons, L.L.C. | $49.62 | 2019-2023 | Camzyos |
| Abiomed | $49.02 | 2025 | |
| Medtronic, INC. | $47.43 | 2021-2022 | |
| Astellas Pharma US INC | $42.44 | 2019 | |
| Medtronic Vascular, INC. | $37.64 | 2020 | |
| Janssen Pharmaceuticals, INC | $30.75 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $29.68 | 2024 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Siemens Medical Solutions USA, INC. | $25.32 | 2021 | |
| Veryan Medical Incorporated | $24.20 | 2023 | Biomimics 3d Vascular Stent System |
| Cvrx, INC. | $23.64 | 2025 | Barostim Neo System |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $21.30 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.60 | 2021 | |
| Atricure, INC. | $14.39 | 2024 | |
| Kiniksa Pharmaceuticals, Ltd. | $12.72 | 2023 | Arcalyst |
| Regeneron Healthcare Solutions, INC. | $12.45 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Hemminger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.